Your browser doesn't support javascript.
loading
Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Sen, Taha; Ju, Wenjun; Nair, Viji; Ladd, Patricia; Menon, Rajasree; Otto, Edgar A; Pyle, Laura; Vigers, Tim; Nelson, Robert G; Arnott, Clare; Neal, Bruce; Hansen, Michael K; Kretzler, Matthias; Bjornstad, Petter; Heerspink, Hiddo J L.
Affiliation
  • Sen T; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Ju W; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
  • Nair V; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Ladd P; Department of Radiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Menon R; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
  • Otto EA; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Pyle L; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA; Section of Endocrinology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Vigers T; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA; Section of Endocrinology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Nelson RG; Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
  • Arnott C; The George Institute for Global Health, University New South Wales (UNSW), Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Neal B; The George Institute for Global Health, University New South Wales (UNSW), Sydney, New South Wales, Australia.
  • Hansen MK; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Kretzler M; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: kretzler@med.umich.edu.
  • Bjornstad P; Section of Endocrinology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA. Electronic address: Petter.M.Bjornstad@cuanschu
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands; The George Institute for Global Health, University New South Wales (UNSW), Sydney, New South Wales, Australia. Electronic address: h.j.lambers.heerspink@umcg.nl
Kidney Int ; 104(4): 828-839, 2023 10.
Article in En | MEDLINE | ID: mdl-37543256
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Kidney Int Year: 2023 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Kidney Int Year: 2023 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos